An Anti-Psychotic Drug With its Own Issues: AstraZeneca’s Seroquel – German Patent Tossed

AstraZeneca’s (AZN) big selling Seroquel, an anti-psychotic drug with annual sales well over $1 billion, suffered the loss of its German patent, according to an AP news dispatch.

The setback comes in the wake of questions about Seroquel’s heavy prescribing by the U.S. military for off-label uses, as YCharts has reported.

AZN Chart

AZN data by YCharts

AstraZeneca has struggled more than most drug makers – more, according to this brilliant Forbes analysis, than Pfizer (PFE), GlaxoSmithKline (GSK), Sanofi (SNY) or Johnson & Johnson (JNJ) -- to develop new drugs and replace those with expiring patents.

From the editors of YCharts, which includes the just-released YCharts Pro Platinum for professional investors.

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.